The present invention is directed to kit, drug combinations and methods for promoting endogenous bone marrow (BM)-derived vasculogenic progenitor cell (PC) mobilization, sensitization of such cells and chemotaxis to the site of an injury such as injuries associated with osteointegration of implants and associated soft tissues, fat grafting and endochondral bone injuries and disease.
